Kiniksa Pharmaceuticals

100 Hayden Ave
Lexington,  MA  02421

United States
  • Booth: ES8098

Kiniksa Pharmaceuticals is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from devastating and debilitating diseases with significant unmet medical need. At Booth #7049, Kiniksa will be highlighting efforts related to recurrent pericarditis, a rare autoinflammatory condition with no FDA-approved therapies. Current treatments, utilizing nonspecific inhibitors of inflammation, can result in significant morbidity with chronic use. Kiniksa is evaluating the efficacy and safety of rilonacept in participants with recurrent pericarditis in a trial called RHAPSODY ( Identifier: NCT03737110). Rilonacept in recurrent pericarditis is an investigational drug.

 Additional Info

ACC.20/WCC Learning Pathways? (select all that apply)
Interventional Cardiology